1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com
News Release [BD LOGO]
Helping all people
live healthy lives
Contact:
Patricia A. Spinella, Investor Relations - 201-847-5453
Colleen White, Corporate Communications - 201-847-5369
BD ANNOUNCES FISCAL SECOND QUARTER RESULTS
Franklin Lakes, NJ (April 22, 2004) - BD (Becton, Dickinson and Company) (NYSE:
BDX) today reported record quarterly revenues of $1.271 billion for the fiscal
second quarter ended March 31, 2004, an increase of 12 percent from the same
period a year ago. At constant foreign exchange rates, revenues increased 6
percent. Revenue growth in all segments benefited from favorable foreign
currency translation, particularly with respect to the Euro.
"We are pleased with the Company's continued strong performance in the second
quarter. Solid revenue growth in our BD Medical and BD Biosciences segments
reflects contributions from several key areas - prefillable drug delivery
devices, diabetes related products and our BD FACSAria'TM' cell sorter," said
Edward J. Ludwig, Chairman, President and Chief Executive Officer. "Strong
revenue growth in nearly all of our international regions was another driving
force."
Diluted earnings per share and net income for the quarter were 62 cents and $165
million, respectively. For the same period in fiscal 2003, diluted earnings per
share were 54 cents and net income was $142 million.
Q2 Segment Results
In the BD Medical segment, worldwide revenues for the quarter were $683 million,
representing an increase of 13 percent over the prior year period. Included in
BD Medical revenues were U.S. safety-engineered product sales of $107 million,
as compared with $98 million in the prior year's quarter, which was offset in
part by reduced sales of certain conventional devices in the U.S. due to the
transition to safety-engineered devices. Also contributing to the growth of the
segment were increased sales of diabetes related products and prefillable drug
delivery devices.
In the BD Diagnostics segment, worldwide revenues for the quarter were $383
million, representing an increase of 7 percent over the prior year period.
Revenue growth of 11 percent in the Preanalytical Systems unit of the segment
included U.S. safety-engineered device sales of $75 million, compared with $68
million in the prior year's quarter, which was offset in part by reduced sales
of conventional devices in the U.S. due to the transition to safety-engineered
devices. After having experienced a 31 percent increase in the first quarter,
due in large part to earlier than usual and exceptionally strong sales of
respiratory and flu diagnostic tests in the U.S. and Japan, revenues in the
Diagnostic Systems unit of the segment increased 3 percent in the second
quarter. For the first half of fiscal 2004, the Diagnostic Systems unit reported
17 percent revenue growth.
In the BD Biosciences segment, worldwide revenues were $205 million,
representing an increase of 17 percent over the prior year period. These results
reflected broad market acceptance of the BD FACSAria'TM' cell sorter, which BD
Biosciences began shipping at the end of the second fiscal quarter of 2003,
along with strong sales of flow cytometry reagents in the Immunocytometry
Systems and Pharmingen units. Revenue growth was also driven by Discovery
Labware products.
Q2 Geographic Results
Second quarter revenues in the U.S. of $619 million represented an increase of 7
percent over the prior year period. Revenues outside the U.S. of $651 million
represented an increase of 17 percent over the prior year period, or 4 percent
at constant foreign exchange rates. International revenues in the second quarter
benefited from favorable foreign exchange in substantially all regions.
Excluding the impact of favorable foreign exchange, revenues increased in
substantially all regions.
Six-month Results
For the six-month period ended March 31, 2004, reported revenues were $2.470
billion, a 13 percent increase over the same period a year ago, or 6 percent at
constant foreign exchange rates. Diluted earnings per share for the six-month
period were $1.10. For the same period in fiscal 2003, diluted earnings per
share were 97 cents. Included in the first half results of fiscal 2004 was a
first quarter charge of 11 cents related to certain actions taken in connection
with our blood glucose monitoring products. Excluding the charge of 11 cents,
pro forma diluted earnings per share for the first half of fiscal 2004 were
$1.21.
Fiscal 2004 Outlook
The Company estimates that its reported diluted earnings per share for fiscal
2004, which includes a charge of 11 cents per share relating to its blood
glucose monitoring products, will increase in the range of 10 to 12 percent over
the prior period. This estimate is based on fiscal 2003 pro forma earnings per
share of $2.15, which excludes 8 cents of non-cash charges related to the
write-down of certain intangible assets and inventory in the BD Biosciences
segment.
Conference Call Information
A conference call regarding BD's second quarter results and its expectations for
the full fiscal year will be broadcast live on BD's website,
www.bd.com/investors, at 10:00 a.m. (ET) Thursday, April 22, 2004. The
conference call will be available for replay on BD's website at
www.bd.com/investors or at 1-800-283-9732 (domestic) and 1-402-998-1159
(international) through April 29, 2004.
This news release contains certain non-GAAP financial measures. A reconciliation
of these and other measures to the comparable GAAP measures is included in the
attached financial tables.
BD is a medical technology company that serves healthcare institutions, life
science researchers, clinical laboratories, industry and the general public. BD
manufactures and sells a broad range of medical supplies, devices, laboratory
equipment and diagnostic products. For the fiscal year ended September 30, 2003,
BD reported total revenues of $4.528 billion.
***
This press release, including the section entitled "Fiscal 2004 Outlook,"
contains certain forward-looking statements (as defined under Federal securities
laws) regarding BD's performance, including future revenues, products and
income, or events or developments that BD expects to occur or anticipates
occurring in the future. All such statements are based upon current expectations
of BD and involve a number of business risks and uncertainties. Actual results
could vary materially from anticipated results described, implied or projected
in any forward-looking statement. Factors that could cause actual results to
vary materially from any forward-looking statement include, but are not limited
to: competitive factors; pricing and market share pressures; uncertainties of
litigation; changes in BD's sales volume and product mix; BD's ability to
achieve its cost savings objectives; changes in regional, national or foreign
economic conditions; increases in energy costs; fluctuations in costs and
availability of raw materials and in BD's ability to maintain favorable supplier
arrangements and relationships; changes in interest or foreign currency exchange
rates; delays in product introductions; and changes in healthcare or other
governmental regulation, as well as other factors discussed in this press
release and in BD's filings with the Securities and Exchange Commission. We do
not intend to update any forward-looking statements.
BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)
Three Months Ended March 31,
----------------------------------
2004 2003 % Change
- --------------------------------------------------------------------------------
REVENUES $1,270,523 $1,134,041 12.0
Cost of products sold 638,049 578,428 10.3
Selling and administrative 338,628 298,798 13.3
Research and development 62,554 60,034 4.2
- --------------------------------------------------------------------------------
TOTAL OPERATING COSTS
AND EXPENSES 1,039,231 937,260 10.9
- --------------------------------------------------------------------------------
OPERATING INCOME 231,292 196,781 17.5
Interest expense, net (7,961) (8,653) (8.0)
Other expense, net (3,118) (1,847) NM
- --------------------------------------------------------------------------------
INCOME BEFORE
INCOME TAXES 220,213 186,281 18.2
Income tax provision 55,053 44,241 24.4
- --------------------------------------------------------------------------------
NET INCOME $ 165,160 $ 142,040 16.3
- --------------------------------------------------------------------------------
EARNINGS PER SHARE
Basic $ 0.65 $ 0.56 16.1
Diluted $ 0.62 $ 0.54 14.8
- --------------------------------------------------------------------------------
AVERAGE SHARES OUTSTANDING
Basic 253,294 254,694
Diluted 265,055 263,369
- --------------------------------------------------------------------------------
NM - Not Meaningful
Page 1
BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)
Six Months Ended March 31,
----------------------------------
2004 2003 % Change
- --------------------------------------------------------------------------------
REVENUES $2,470,054 $2,185,689 13.0
Cost of products sold 1,278,933 1,128,467 13.3
Selling and administrative 668,248 582,979 14.6
Research and development 123,207 119,879 2.8
- --------------------------------------------------------------------------------
TOTAL OPERATING COSTS
AND EXPENSES 2,070,388 1,831,325 13.1
- --------------------------------------------------------------------------------
OPERATING INCOME 399,666 354,364 12.8
Interest expense, net (16,890) (17,286) (2.3)
Other expense, net (3,164) (1,763) NM
- --------------------------------------------------------------------------------
INCOME BEFORE
INCOME TAXES 379,612 335,315 13.2
Income tax provision 89,050 79,637 11.8
- --------------------------------------------------------------------------------
NET INCOME $ 290,562 $ 255,678 13.6
- --------------------------------------------------------------------------------
EARNINGS PER SHARE
Basic $ 1.15 $ 1.00 15.0
Diluted $ 1.10 $ 0.97 13.4
- --------------------------------------------------------------------------------
AVERAGE SHARES OUTSTANDING
Basic 252,710 254,994
Diluted 263,763 263,328
- --------------------------------------------------------------------------------
NM - Not Meaningful
Page 2
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)
Three Months Ended March 31,
----------------------------------
2004 2003 % Change
----------------------------------
BD MEDICAL
United States $ 320,687 $ 292,794 9.5
International 361,954 309,025 17.1
- --------------------------------------------------------------------------------
TOTAL $ 682,641 $ 601,819 13.4
- --------------------------------------------------------------------------------
BD DIAGNOSTICS
United States $ 211,419 $ 206,206 2.5
International 171,456 150,594 13.9
- --------------------------------------------------------------------------------
TOTAL $ 382,875 $ 356,800 7.3
- --------------------------------------------------------------------------------
BD BIOSCIENCES
United States $ 87,317 $ 78,545 11.2
International 117,690 96,877 21.5
- --------------------------------------------------------------------------------
TOTAL $ 205,007 $ 175,422 16.9
- --------------------------------------------------------------------------------
TOTAL REVENUES
United States $ 619,423 $ 577,545 7.3
International 651,100 556,496 17.0
- --------------------------------------------------------------------------------
TOTAL $1,270,523 $1,134,041 12.0
- --------------------------------------------------------------------------------
Page 3
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)
Six Months Ended March 31,
----------------------------------
2004 2003 % Change
----------------------------------
BD MEDICAL
United States $ 624,435 $ 589,220 6.0
International 685,074 584,236 17.3
- --------------------------------------------------------------------------------
TOTAL $1,309,509 $1,173,456 11.6
- --------------------------------------------------------------------------------
BD DIAGNOSTICS
United States $ 424,336 $ 397,738 6.7
International 359,484 290,716 23.7
- --------------------------------------------------------------------------------
TOTAL $ 783,820 $ 688,454 13.9
- --------------------------------------------------------------------------------
BD BIOSCIENCES
United States $ 162,346 $ 147,882 9.8
International 214,379 175,897 21.9
- --------------------------------------------------------------------------------
TOTAL $ 376,725 $ 323,779 16.4
- --------------------------------------------------------------------------------
TOTAL REVENUES
United States $1,211,117 $1,134,840 6.7
International 1,258,937 1,050,849 19.8
- --------------------------------------------------------------------------------
TOTAL $2,470,054 $2,185,689 13.0
- --------------------------------------------------------------------------------
Page 4
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended March 31,
(Unaudited; Amounts in thousands)
United States
------------------------------
2004 2003 % Change
------------------------------
BD MEDICAL
Medical Surgical Systems $196,418 $180,731 8.7
Diabetes Care 88,730 83,658 6.1
Pharmaceutical Systems 30,276 22,795 32.8
Ophthalmic Systems 5,263 5,610 (6.2)
- --------------------------------------------------------------------------------
TOTAL $320,687 $292,794 9.5
- --------------------------------------------------------------------------------
BD DIAGNOSTICS
Preanalytical Systems $109,464 $102,958 6.3
Diagnostic Systems 101,955 103,248 (1.3)
- --------------------------------------------------------------------------------
TOTAL $211,419 $206,206 2.5
- --------------------------------------------------------------------------------
BD BIOSCIENCES
Discovery Labware $ 24,465 $ 23,226 5.3
Immunocytometry Systems 36,129 29,141 24.0
Clontech 8,234 8,399 (2.0)
Pharmingen 18,489 17,779 4.0
- --------------------------------------------------------------------------------
TOTAL $ 87,317 $ 78,545 11.2
- --------------------------------------------------------------------------------
TOTAL UNITED STATES $619,423 $577,545 7.3
- --------------------------------------------------------------------------------
Page 5
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)
International
-------------------------------------------------------
% Change
---------------------------------
2004 2003 Reported FX Neutral FX Impact
-------------------------------------------------------
BD MEDICAL
Medical Surgical Systems $187,062 $160,667 16.4 4.6 11.8
Diabetes Care 61,338 50,174 22.3 7.5 14.8
Pharmaceutical Systems 105,100 91,011 15.5 0.1 15.4
Ophthalmic Systems 8,454 7,173 17.9 4.0 13.9
- -------------------------------------------------------------------------------------
TOTAL $361,954 $309,025 17.1 3.7 13.4
- -------------------------------------------------------------------------------------
BD DIAGNOSTICS
Preanalytical Systems $ 86,479 $ 73,099 18.3 4.1 14.2
Diagnostic Systems 84,977 77,495 9.7 (1.5) 11.2
- -------------------------------------------------------------------------------------
TOTAL $171,456 $150,594 13.9 1.2 12.7
- -------------------------------------------------------------------------------------
BD BIOSCIENCES
Discovery Labware $ 24,088 $ 20,160 19.5 6.3 13.2
Immunocytometry Systems 67,434 54,339 24.1 10.5 13.6
Clontech 8,553 8,889 (3.8) (14.3) 10.5
Pharmingen 17,615 13,489 30.6 14.7 15.9
- -------------------------------------------------------------------------------------
TOTAL $117,690 $ 96,877 21.5 7.9 13.6
- -------------------------------------------------------------------------------------
TOTAL INTERNATIONAL $651,100 $556,496 17.0 3.8 13.2
- -------------------------------------------------------------------------------------
Page 6
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)
Total
-----------------------------------------------------------
% Change
---------------------------------
2004 2003 Reported FX Neutral FX Impact
-----------------------------------------------------------
BD MEDICAL
Medical Surgical Systems $ 383,480 $ 341,398 12.3 6.7 5.6
Diabetes Care 150,068 133,832 12.1 6.6 5.5
Pharmaceutical Systems 135,376 113,806 19.0 6.6 12.4
Ophthalmic Systems 13,717 12,783 7.3 (0.5) 7.8
- ----------------------------------------------------------------------------------------
TOTAL $ 682,641 $ 601,819 13.4 6.5 6.9
- ----------------------------------------------------------------------------------------
BD DIAGNOSTICS
Preanalytical Systems $ 195,943 $ 176,057 11.3 5.4 5.9
Diagnostic Systems 186,932 180,743 3.4 (1.4) 4.8
- ----------------------------------------------------------------------------------------
TOTAL $ 382,875 $ 356,800 7.3 2.0 5.3
- ----------------------------------------------------------------------------------------
BD BIOSCIENCES
Discovery Labware $ 48,553 $ 43,386 11.9 5.8 6.1
Immunocytometry Systems 103,563 83,480 24.1 15.2 8.9
Clontech 16,787 17,288 (2.9) (8.3) 5.4
Pharmingen 36,104 31,268 15.5 8.6 6.9
- ----------------------------------------------------------------------------------------
TOTAL $ 205,007 $ 175,422 16.9 9.4 7.5
- ----------------------------------------------------------------------------------------
TOTAL REVENUES $1,270,523 $1,134,041 12.0 5.5 6.5
- ----------------------------------------------------------------------------------------
Page 7
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Six Months Ended March 31,
(Unaudited; Amounts in thousands)
United States
----------------------------------
2004 2003 % Change
----------------------------------
BD MEDICAL
Medical Surgical Systems $ 394,937 $ 373,482 5.7
Diabetes Care 163,579 159,154 2.8
Pharmaceutical Systems 54,631 44,322 23.3
Ophthalmic Systems 11,288 12,262 (7.9)
- --------------------------------------------------------------------------------
TOTAL $ 624,435 $ 589,220 6.0
- --------------------------------------------------------------------------------
BD DIAGNOSTICS
Preanalytical Systems $ 216,091 $ 203,981 5.9
Diagnostic Systems 208,245 193,757 7.5
- --------------------------------------------------------------------------------
TOTAL $ 424,336 $ 397,738 6.7
- --------------------------------------------------------------------------------
BD BIOSCIENCES
Discovery Labware $ 47,880 $ 46,346 3.3
Immunocytometry Systems 64,897 52,340 24.0
Clontech 15,087 16,262 (7.2)
Pharmingen 34,482 32,934 4.7
- --------------------------------------------------------------------------------
TOTAL $ 162,346 $ 147,882 9.8
- --------------------------------------------------------------------------------
TOTAL UNITED STATES $1,211,117 $1,134,840 6.7
- --------------------------------------------------------------------------------
Page 8
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Six Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)
International
-----------------------------------------------------------
% Change
---------------------------------
2004 2003 Reported FX Neutral FX Impact
-----------------------------------------------------------
BD MEDICAL
Medical Surgical Systems $ 363,386 $ 313,435 15.9 4.0 11.9
Diabetes Care 119,515 94,223 26.8 11.2 15.6
Pharmaceutical Systems 185,944 162,729 14.3 (1.4) 15.7
Ophthalmic Systems 16,229 13,849 17.2 3.9 13.3
-----------------------------------------------------------
TOTAL $ 685,074 $ 584,236 17.3 3.6 13.7
-----------------------------------------------------------
BD DIAGNOSTICS
Preanalytical Systems $ 164,832 $ 139,279 18.3 4.3 14.0
Diagnostic Systems 194,652 151,437 28.5 15.5 13.0
-----------------------------------------------------------
TOTAL $ 359,484 $ 290,716 23.7 10.1 13.6
-----------------------------------------------------------
BD BIOSCIENCES
Discovery Labware $ 45,556 $ 38,915 17.1 3.8 13.3
Immunocytometry Systems 120,810 95,192 26.9 13.3 13.6
Clontech 16,053 16,781 (4.3) (14.7) 10.4
Pharmingen 31,960 25,009 27.8 11.8 16.0
-----------------------------------------------------------
TOTAL $ 214,379 $ 175,897 21.9 8.3 13.6
-----------------------------------------------------------
TOTAL INTERNATIONAL $1,258,937 $1,050,849 19.8 6.2 13.6
-----------------------------------------------------------
Page 9
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Six Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)
Total
-----------------------------------------------------------
% Change
---------------------------------
2004 2003 Reported FX Neutral FX Impact
-----------------------------------------------------------
BD MEDICAL
Medical Surgical Systems $ 758,323 $ 686,917 10.4 4.9 5.5
Diabetes Care 283,094 253,377 11.7 5.9 5.8
Pharmaceutical Systems 240,575 207,051 16.2 3.8 12.4
Ophthalmic Systems 27,517 26,111 5.4 (1.6) 7.0
-----------------------------------------------------------
TOTAL $1,309,509 $1,173,456 11.6 4.8 6.8
-----------------------------------------------------------
BD DIAGNOSTICS
Preanalytical Systems $ 380,923 $ 343,260 11.0 5.3 5.7
Diagnostic Systems 402,897 345,194 16.7 11.0 5.7
-----------------------------------------------------------
TOTAL $ 783,820 $ 688,454 13.9 8.1 5.8
-----------------------------------------------------------
BD BIOSCIENCES
Discovery Labware $ 93,436 $ 85,261 9.6 3.6 6.0
Immunocytometry Systems 185,707 147,532 25.9 17.1 8.8
Clontech 31,140 33,043 (5.8) (11.0) 5.2
Pharmingen 66,442 57,943 14.7 7.8 6.9
-----------------------------------------------------------
TOTAL $ 376,725 $ 323,779 16.4 9.0 7.4
-----------------------------------------------------------
TOTAL REVENUES $2,470,054 $2,185,689 13.0 6.5 6.5
-----------------------------------------------------------
Page 10
BECTON DICKINSON AND COMPANY
RECONCILIATION TO PRO FORMA AMOUNTS
Six Months Ended March 31,
(Unaudited)
2004
--------------------------------
As BGM Excluding
Reported Charges * Charges
--------------------------------
Diluted EPS $1.10 $0.11 $1.21
* Relates to the fiscal 2004 charge associated with blood glucose monitoring
(BGM) products.
BECTON DICKINSON AND COMPANY
RECONCILIATION TO PRO FORMA AMOUNTS
Twelve Months Ended September 30,
(Unaudited)
2003
-------------------------------
As Non-cash Excluding
Reported Charges** Charges
-------------------------------
Diluted EPS $2.07 $0.08 $2.15
** Relates to the fiscal 2003 write-down of certain intangible assets and
inventory in the BD Biosciences segment.
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Six Months Ended March 31,
(Unaudited; Amounts in thousands)
2004
-----------------------------------
As BGM Excluding
Reported Charges * Charges
-----------------------------------
Gross Profit $1,191,121 $45,024 $1,236,145
as a % of revenues 48.2% 50.0%
Operating Income 399,666 45,024 444,690
as a % of revenues 16.2% 18.0%
Net Income 290,562 27,915 318,477
as a % of revenues 11.8% 12.9%
* Relates to the fiscal 2004 charge associated with blood glucose monitoring
(BGM) products.
Page 11